The mechanisms by which hypoxic tumours evade immunological pressure and anti-tumour immunity remain elusive. Here, we report that two hypoxia-responsive microRNAs, miR-25 and miR-93, are important for establishing an immunosuppressive tumour microenvironment by downregulating expression of the DNA sensor cGAS. Mechanistically, miR-25/93 targets NCOA3, an epigenetic factor that maintains basal levels of cGAS expression, leading to repression of cGAS during hypoxia. This allows hypoxic tumour cells to escape immunological responses induced by damage-associated molecular pattern molecules, specifically the release of mitochondrial DNA. Moreover, restoring cGAS expression results in an anti-tumour immune response. Clinically, decreased levels of cGAS are associated with poor prognosis for patients with breast cancer harbouring high levels of miR-25/93. Together, these data suggest that inactivation of the cGAS pathway plays a critical role in tumour progression, and reveal a direct link between hypoxia-responsive miRNAs and adaptive immune responses to the hypoxic tumour microenvironment, thus unveiling potential new therapeutic strategies.
The ability of cancer cells to evade immune responses is critical for the emergence of malignant phenotypes 1 . Cancer cells can escape both innate and adaptive immune responses by deregulating immune effector cells and immunosuppressive cells, as well as molecules responsible for cancer cell recognition and elimination 2 . Hypoxia contributes to immunosuppression within tumours, helping shield cancer cells from immune attack and inhibiting immune killing functions [3] [4] [5] . For example, immunosuppressive cells (for example, regulatory T cells) accumulate within hypoxic regions of tumours where they promote tumour progression [6] [7] [8] [9] and activate immune tolerance mechanisms that enable cancer cells to evade host immunosurveillance. Despite recent advances, the molecular mechanisms underlying hypoxiainduced immune escape are not yet fully understood.
MicroRNAs (miRNAs) regulate a variety of cellular processes, including immune cell differentiation, immune responses to infection, and the development of immune disorders 10, 11 . In the context of tumorigenesis, dysregulated miRNAs promote tumour progression by regulating cancer pathways associated with tumour malignancy 12 .
A recent screen for hypoxia-regulated miRNAs in breast cancer cells revealed that hypoxia modulates miRNA function during breast cancer progression 13 . Hypoxia-responsive miRNAs regulate a complex spectrum of candidate target genes, including those involved in proliferation, apoptosis, metabolism and migration 14 . Here we identify hypoxia-responsive miR-25 and miR-93 as critical factors in suppressing the expression of cyclic GMP-AMP synthase (cGAS) through a pathway that requires TET1 and NCOA3. In this way, these miRNAs promote immune escape of hypoxic tumours from damageassociated molecular pattern molecule (DAMP)-induced immunological stress, ultimately leading to the formation of an immunosuppressive tumour microenvironment.
RESULTS

Hypoxia signalling induces immunosuppressive phenotypes
Recent findings suggest that hypoxia/HIF-1 signalling suppresses host defence against cancer 9, 15 . To prove this concept, we examined associations between hypoxic tumours and immunosuppression. We Il-10
Il-17
Il-1 Figure 1 miR-25/93 induced by hypoxia drives immunosuppression. (a) Top: correlation between regions of hypoxia (defined by hypoxyprobe) and regions of high HIF-1α in murine tumour samples. Bottom: screening for hypoxic murine tumour samples. Endogenous HIF-1α was used as an indicator for hypoxia. E0771 cells were used for tumour formation. Scale bars, 50 µm. N, non-hypoxic sample; H, hypoxic sample. (b,c) Gene expression analysis for selected genes responsible for either anti-tumour immunity or tumourpromoting effects in hypoxic tumour samples, compared with non-hypoxic tumour samples. Anti-tumour immunity factors include Ifn-g, Il-12, Cxcl10, lfit1 and Tbx21. Tumour-promoting factors include Il-10, Il-1 and Il-17.
(d) The percentage of effector CD8 + cytotoxic T cells was decreased in HIF-1α-overexpressing tumours. Changes in effector CD8 + cytotoxic T cells were normalized to total CD8 + T-cell proportions. Effector CD8 + cytotoxic T cells were defined by the production of TNF (also known as TNF-α) and IFN-γ. E0771 cells expressing HIF-1α or empty vector were used for tumour formation. (e) HIF-1α-overexpressing tumours showed significantly higher recruitment of CD4 + Foxp3 + Tregs. (f) Gene expression analysis for anti-tumour immunity factors in whole-tumour homogenates derived from HIF-1α-overexpressing tumours or control tumours. (g) The level of tumourpromoting factors was increased in HIF-1α-overexpressing tumours versus control tumours. For b,c, control: n = 8 tumours from 8 different animals, hypoxic: n = 5 tumours from 5 different animals. For d,e, control: n = 5 tumours from 5 different animals, HIF-1α: n = 7 tumours from 7 different animals. For f,g, control: n = 8 tumours from 8 different animals; HIF-1α: n = 8 tumours from 8 different animals. Samples were compared using twotailed Student's t-test. * P < 0.05, * * P < 0.01, * * * P < 0.001. The image shown in a is representative of three independent experiments. Unprocessed original scans of western blots are available in Supplementary Fig. 9 . Statistics source data are available in Supplementary Table 4 . Data shown in b,c,e-g represent the mean. For d, data are represented as mean ± s.d.
identified hypoxic breast tumour samples on the basis of levels of HIF-1α and assessed the expression of an array of inflammatory and immune mediators. This analysis revealed decreased levels of Ifn-g , an anti-tumour factor, as well as decreased levels of several factors known to drive anti-tumour immunity, such as Il-12, Cxcl10, Ifit1 and Tbx21 (ref. 16) . In contrast, Il-10, a tumour-promoting factor, as well as Il-1β and Il-17, were increased ( Fig. 1a-c) . As a second means of studying hypoxic cancer cells, we subcutaneously inoculated wild-type mice with murine breast cancer cells (E0771) that overexpress a constitutively active form of HIF-1α (ref. 17) . Because hypoxia results in the recruitment of immunosuppressive cells 4 , we characterized tumour-infiltrating immune cells (TICs). Fluorescence-activated cell sorting (FACS) analysis of tumour biopsies indicated an increase in CD11b + Ly6G − Ly6C high monocytic myeloidderived suppressor cells (MDSCs) in HIF-1α-overexpressing tumours (compared with control tumours), whereas HIF-1α did not affect levels of CD11b + F4/80 + tumour-associated macrophages or CD11b + Ly6G + Ly6C low granulocytic MDSCs ( Supplementary Fig. 1a -c). The population of effector CD8 + T cells was decreased in HIF-1αoverexpressing tumours, accompanied by a change in the percentage of tumour-infiltrating CD8 + T cells, whereas the percentage of CD4 + T cells remained the same ( Fig. 1d and Supplementary Fig. 1d,e ). Furthermore, we found greater numbers of CD4 + Foxp3 + regulatory T cells (Tregs) in HIF-1α-overexpressing tumours ( Fig. 1e ), consistent with previous reports showing enhanced recruitment of Tregs by hypoxia 9, 18 . We also analysed these tumours and consistently observed immunosuppressive gene expression profiles, as shown by decreased levels of anti-tumour immunity factors and increased levels of tumourpromoting factors (Fig. 1f,g) . Collectively, these results indicate that hypoxia/HIF-1α promotes immunosuppression during breast cancer formation in vivo.
Hypoxia-responsive miR-25/93 functions as an immunosuppressive factor
To identify bona fide hypoxia-regulated miRNAs, we performed small RNA sequencing using different cellular models, including hypoxic cells and HIF-1α-overexpressing cells, as described previously 19 ( Supplementary Fig. 2a ). Ingenuity pathway analysis for selected miRNA candidates revealed correlations between these miRNAs and breast cancer formation, as well as oncogenic signalling pathways. ( Supplementary Fig. 2b,c) . These data led us to focus on the miR-106b-25/miR-17-92 clusters, which are deregulated in human cancer 20 . It is well established that the miR-17-92 cluster plays roles in the development of the immune system and cancer; however, the role of the miR-106b-25 cluster remains largely unknown. We identified miR-25 and miR-93 as potential targets of hypoxia, as expression of these miRNAs was markedly increased in hypoxic conditions ( Fig. 2a-c and Supplementary Fig. 2d ). However, hypoxia did not affect levels of miR-106b, another member of the miR-106b-25 cluster. Short hairpin RNA (shRNA)-mediated knockdown of HIF-1α abolished the ability of hypoxia to induce miR-25/93 expression (Supplementary Fig. 2e ), thereby indicating that miR-25/93 are hypoxiaresponsive miRNAs. Inhibiting miR-25/93 slowed tumour growth in wild-type mice. Importantly, this effect was compromised in immune-deficient mice, suggesting that miR-25/93 inhibits host immune responses against the tumour ( Fig. 2d,e ). To explore the role of miR-25/93 in hypoxiarelevant tumour immune responses, we inhibited miR-25/93 in tumours overexpressing HIF-1α. This compromised the ability of HIF-1α to: enhance tumour growth ( Fig. 2f ); decrease levels of effector CD8 + T cells; and increase recruitment of Tregs ( Fig. 2g,h) . Furthermore, we analysed the profile of TICs in tumours constitutively overexpressing miR-25/93. Monocytic MDSCs consistently accumulated in miR-25/93-overexpressing tumours; this was accompanied by an increased rate of tumour growth ( Fig. 2i and Supplementary Fig. 3a,b ). In contrast, miR-25/93 overexpression did not affect tumour-associated macrophages or granulocytic MDSCs (Supplementary Fig. 3c,d ). Overexpression of miR-25/93 decreased the population of effector CD8 + T cells, alongside changes in the percentage of tumour-infiltrating CD4 + T cells and CD8 + T cells ( Fig. 2j and Supplementary Fig. 3e ,f). Similar to hypoxic tumours, miR-25/93 overexpression resulted in a greater number of Tregs ( Fig. 2k ). Gene expression analysis of miR-25/93-overexpressing tumours consistently indicated an immune regulatory gene signature associated with hypoxia ( Supplementary Fig. 3g ,h). Together, these results indicate that elevated levels of miR-25/93 in tumour cells drive the establishment of an immunosuppressive environment.
TET1 is important for the upregulation of miR-25/93 in response to hypoxia
To investigate the molecular mechanism underlying hypoxia-induced miR-25/93 expression, we first examined the role of HIF-1α. HIF-1α expression was required for hypoxia to induce the expression of miR-25/93 ( Supplementary Fig. 2e ). However, we did not observe significant HIF-1α binding to the miR-25/93 genomic region, as compared with the VEGF promoter, which HIF-1α bound tightly in response to hypoxia ( Supplementary Fig. 4a ). This suggests that hypoxia regulates miR-25/93 in a HIF-1α-independent manner. It is known that hypoxia can regulate miRNA biogenesis via epigenetic mechanisms 21 . Recent findings indicate that TET-mediated local 5-hydroxymethylcytosine (5hmC) changes are important for the regulation of hypoxia-responsive genes 19, 22 . Thus, we examined the role of 5hmC and TET proteins in this context. hMeDIP-seq analysis as well as conventional hydroxymethylated DNA immunoprecipitation (hMeDIP) quantitative PCR (qPCR) analysis showed an increase in 5hmC levels within the miR-25/93 genomic loci in hypoxic cells ( Supplementary Fig. 4b,c ). Chromatin immunoprecipitation (ChIP)-qPCR analysis for TET1 and TET3 indicated increased binding of TET1, but not TET3, to these regions ( Supplementary  Fig. 4d ). In support of these findings, silencing TET1, but not TET3, prevented hypoxia-induced upregulation of miR-25/93 expression ( Supplementary Fig. 4e-h ). Furthermore, the expression of wild-type TET1, but not an inactive form of TET1, restored the hypoxic epigenetic phenotype ( Supplementary Fig. 4i ). Together, these results indicate an epigenetic layer of regulation in determining miR-25/93 levels in hypoxic conditions.
A hypoxia-TET1-miR-25/93 signalling axis represses cGAS-dependent immunity Next, we sought to identify the downstream signalling pathways that contribute to miR-25/93-driven immunosuppression. RNA-seq analysis in breast cancer cells overexpressing miR-25/93 was conducted to identify miRNA-responsive genes ( Fig. 3a ). Gene ontology analysis of these downstream genes highlighted biological processes related to transcription factor activity, cell adhesion and so on ( Fig. 3b ). Validation of these potential target genes by qPCR indicated that cGAS, which is critical for the innate immune system to detect cytosolic DNA 23, 24 , was a promising downstream target for miR-25/93. Decreased levels of cGAS were detected in breast cancer cells overexpressing miR-25/93 or in hypoxic conditions ( Fig. 3c-f ). In line with this, shRNA-mediated inhibition of miR-25/93 restored cGAS expression in hypoxic cancer cells ( Fig. 3g,h ). Because TET1 regulates miR-25/93 expression in hypoxia, we examined the expression of cGAS in TET1-deficient breast cancer cells. As expected, loss of TET1 inhibited hypoxia-induced downregulation of cGAS expression ( Fig. 3i,j ). Furthermore, in tumours overexpressing HIF-1α or miR-25/93, cGAS levels were consistently downregulated ( Fig. 3k,l) . Collectively, these results indicate a role for the hypoxia-TET1-miR-25/93 signalling axis in regulating cGAS. (k) miR-25/93-overexpressing tumours attracted more CD4 + Foxp3 + Tregs than control tumours. For a, n = 3 independent experiments. For b,c, n = 3 tumours from 3 different animals. For g,h, n = 5 tumours from 5 different animals. For j,k, control: n = 10 tumours from 10 different animals; miR-25/93: n = 13 tumours from 13 different animals. For i, n = 8 tumours from 8 different mice for each group. Data shown in a-g,i,j represent the mean ± s.d. of indicated sample numbers. Data in h,k represent the mean. Samples were compared using two-tailed Student's t-test. * P < 0.05, * * P < 0.01, * * * P < 0.001. Statistics source data are available in Supplementary Table 4 .
cGAS serves as a sensor for cytosolic DNA, inducing the production of type I interferons, which lead to innate immunity 24 . Hence, we investigated whether hypoxia attenuates the innate immune response against cytosolic DNA. We used qPCR analysis to assess levels of IFN-β expression, an indicator of cGAS-mediated immune response 24 . Hypoxia treatment inhibited the induction of IFN-β in breast cancer cells ( Fig. 4a ). Given that the TET1-miR-25/93 signalling pathway is required to repress cGAS expression in response to hypoxia, this pathway may also be important for hypoxia-induced repression of innate immunity responses to cytosolic DNA. Indeed, we observed the restoration of hypoxia-induced immune responses in TET1deficient cells (Fig. 4b,c ). Likewise, inhibition of miR-25/93 in hypoxic cells restored the induction of IFN-β in the presence of cytosolic DNA ( Fig. 4d,e ). In support of these observations, we demonstrated that downregulation of cGAS both decreased the innate immune response to cytosolic DNA and enhanced hypoxia-induced immunosuppression ( Fig. 4f,g) . Furthermore, the cytosolic DNAinduced immune response was significantly reduced by knocking down cGAS expression in either MCF7 or MDA-MB-231 cells undergoing miR-25/93 inactivation ( Fig. 4h ,i). Together, these results suggest that repression of cGAS by the TET1-miR-25/93 pathway is crucial for hypoxia to suppress the immune response to cytosolic DNA.
Levels of endogenous DNAs, considered DAMPs, are increased by hypoxia during cancer progression and can trigger the rejection of tumours by the immune system 25, 26 . Recent studies have demonstrated that the cGAS-dependent DNA sensing pathway can also recognize mitochondrial DNA (mtDNA) released by apoptosis 27, 28 . In line with this, hypoxia induces mitophagy and the extensive fragmentation of mitochondria 26, 29, 30 , which may lead to the release of mtDNA into the cytoplasm. We therefore hypothesized that to Supplementary Fig. 9 . Statistics source data are available in Supplementary Table 4 .
relieve immune pressure driven by the accumulation of cytosolic mtDNA, which occurs in the hypoxic tumour microenvironment during cancer progression, cancer cells must suppress the cGASdependent DNA sensing pathway via TET1 and miR-25/93. Thus, we examined whether hypoxia leads to the accumulation of cytosolic mtDNA in cancer cells. qPCR analysis demonstrated increased levels of cytosolic mtDNA in hypoxic breast cancer cells compared with normoxic controls ( Supplementary Fig. 5a ). Consistent with previous findings 29 , hypoxia treatment induced LC3-II and decreased levels of p62, markers of autophagy/mitophagy ( Supplementary Fig. 5b ). To ensure that mtDNA activates the cGAS-dependent immune response, we transfected mtDNA into breast cancer cells and analysed IFN-β levels. The induction of IFN-β in this context indicated that cytosolic mtDNA serves as a trigger for innate immunity ( Supplementary  Fig. 5c ). Notably, repression of miRNA-25/93 restored the induction of IFN-β by cytosolic mtDNA in hypoxic cells ( Supplementary Fig. 5d,e ).
Furthermore, downregulation of cGAS attenuated mtDNA-induced immune response ( Supplementary Fig. 5f ,g), confirming that cGAS acts as an important sensor for cytosolic mtDNA. We reasoned that manipulating miR-25/93 or cGAS levels may alter levels of cytosolic mtDNA, leading to compromised immunosuppression. Thus, we analysed cytoplasmic levels of mtDNA and found similar levels of hypoxiainduced cytoplasmic mtDNA in either miRNA-25/93-inactivated or cGAS-deficient cells, compared with control cells ( Supplementary  Fig. 6a,b ). Together, these results reveal that the TET1-miR-25/93 signalling pathway represses a cGAS-dependent immune response that results from hypoxia-mediated release of mtDNA.
To ensure that cGAS functions to dampen the immunosuppressive microenvironment, we constitutively expressed cGAS in miR-25/93-overexpressing tumours. FACS analysis demonstrated that re-expression of cGAS reversed immunosuppressive phenotypes, as indicated by significantly decreased populations of monocytic Supplementary Table 4 .
MDSCs, along with an increase in effector CD8 + T cells ( Fig. 5a,b ). Likewise, Tregs were decreased in cGAS-re-expressing tumours compared with miR-25/93-overexpressing tumours ( Fig. 5c ). Furthermore, gene expression analysis indicated increased levels of antitumour immunity factors in cGAS-re-expressing tumours, whereas levels of tumour-promoting factors were significantly decreased ( Fig. 5d,e ). As a key effector of cGAS signalling, type I interferons (IFNs) mediate anti-tumour immunity via their immunostimulatory functions 31 . As the immunosuppressive function of miR-25/93 may rely on restrained IFN-stimulated immunosurveillance, we examined levels of INF-β in vivo. We observed decreased levels of INF-β and cGAS in hypoxic tumours and HIF-1α-overexpressing tumours ( Fig. 5f ). INF-β levels were restored in HIF-1α-overexpressing tumours in which miR-25/93 were inhibited, as well as in miR-25/93overexpressing tumours in which cGAS was re-expressed ( Fig. 5g ). To ascertain the role of cGAS-IFN signalling in tumour development, we assessed tumour growth in mice lacking the interferon (alpha and beta) receptor 1 (IFNAR1). Forced expression of miR-25/93 increased tumour cell proliferation in wild-type mice; this effect was reversed by re-expressing cGAS (Fig. 5h ). Loss of IFNAR1 compromised the ability of miR-25/93 to promote tumour progression, supporting the notion that cGAS-IFN signalling inhibits tumour progression ( Fig. 5i ).
In addition, we found that tumours lacking cGAS were more proliferative than control tumours. ( Supplementary Fig. 7a ). As expected, the analysis of TIC profiles in cGAS-deficient tumours revealed a pattern similar to miR-25/93-or HIF-1α-overexpressing tumours ( Supplementary Fig. 7b-d ). Silencing cGAS decreased the percentage of effector CD8 + T cells; this is accompanied by changes in the levels of tumour-infiltrating CD4 + T cells and CD8 + T cells ( Supplementary  Fig. 7e-g) . Likewise, FACS analysis indicated a significant increase in Tregs in cGAS-deficient tumours ( Supplementary Fig. 7h ). Gene expression analysis further showed that downregulation of cGAS recapitulated the immune gene signature that characterizes hypoxic tumours ( Supplementary Fig. 7i-k) .
miR-25/93 indirectly regulates cGAS expression by targeting NCOA3 under hypoxic conditions
Next, we sought to characterize the molecular mechanisms by which miR-25/93 represses cGAS. Analysis of the 3 -UTR of the cGAS gene did not identify a putative miR-25/93target sequence, which led us to conclude that miR-25/93 suppresses cGAS expression by targeting other regulators. In our search for additional factors that regulate cGAS, we noticed that the cGAS promoter region contains an AP-1 biding site. It is unlikely that AP-1 is a key factor in the hypoxiamediated repression of cGAS, but our RNA-seq data indicated that NCOA3, a member of the nuclear receptor co-activator (Ncoa) family that coordinates with AP-1 (ref. 32) , was downregulated in miR-25/93-overexpressing cells (Fig. 6a ). Likewise, hypoxia treatment resulted in decreased levels of NCOA3 ( Fig. 6b ). Analysis of the 3 -UTR associated with the NCOA3 transcript identified conserved target sequences for miR-25/93. A 3 -UTR reporter assay showed that miR-25/93 suppressed NCOA3 reporter activity. Mutating the miR-25/93 target sequences within the NCOA3 3 -UTR abrogated miR-25/93-mediated repression (Fig. 6c ). Together, these results indicate that NCOA3 is a downstream target of miR-25/93. Because NCOA3 functions as a lysine acetyltransferase involved in transcriptional activation 33 , we asked whether NCOA3 regulates cGAS expression in response to hypoxia. We found that ectopic expression of NCOA3 restored the expression of cGAS in response to hypoxia ( Fig. 6d ). ChIP-qPCR analysis revealed decreased levels of NCOA3 binding to the cGAS promoter in hypoxic cancer cells, compared with normoxic controls. This was associated with decreased levels of CBP binding, a protein that interacts with NCOA3, as well as decreased binding of RNA pol II to the cGAS transcription start site ( Fig. 6e-g) . Moreover, two epigenetic modifications indicative of active transcription, H3K27Ac and H3K4me2, are associated with NCOA3 function 34 and were consistently downregulated in hypoxic cells ( Fig. 6h-j) . Re-expression of NCOA3 restored levels of CBP binding to cGAS genomic regions in hypoxic cancer cells ( Fig. 7a,b,f,g) . Likewise, levels of H3K27Ac and H3K4Me2 were restored by re-expression of NCOA3 ( Fig. 7c -e,h-j). Collectively, these results indicate that repression of NCOA3 by miR-25/93 is required for the suppression of cGAS in response to hypoxia.
The biological significance for miR-25/93 and cGAS in clinical tissues
To test the relevance of these findings to human cancer, we first examined the prognostic impact of miR-25/93. Levels of these Supplementary Fig. 9 . Statistics source data are available in Supplementary Table 4 .
miRNAs were correlated with poor prognosis for patients with different types of hypoxia-relevant tumour, such as brain, colon and breast (Fig. 8a) . Notably, higher levels of miR-25 and miR-93 were associated with reduced overall survival in patients with invasive breast carcinoma (Fig. 8b) . We next examined the prognostic impact of cGAS levels for 148 patients with invasive ductal carcinoma (IDC). Levels of cGAS were inversely associated with poor prognosis for these patients (Fig. 8c,d) . Consistent with this result, lower levels of cGAS were correlated with poor survival for cancer patients harbouring elevated levels of miR-93 ( Fig. 8e ), whereas other identified miRNA targets (for example, Bim and PTEN) did not exhibit clinical significance ( Supplementary Fig. 8a,b ), suggesting that the downregulation of cGAS is a biologically relevant factor in miR-25/93driven tumour progression. Collectively, these results support our hypothesis that repression of cGAS by hypoxia-responsive miR-25/93
is critical for establishing an immunosuppressive environment that is associated with cancer progression.
DISCUSSION
The mechanisms by which tumour cells maintain immunological self-tolerance and hinder effective tumour immunity are critical for tumour progression. Here, we uncover a mechanism for hypoxiainduced escape from immunological stress caused by DAMPs (Fig. 8f) . Hypoxia induced the expression of miR-25/93 by increasing 5hmC levels (that is, DNA demethylation) near the miR-25/93 gene via the TET1 protein. Differential regulation of the miR-106b-25 cluster in response to hypoxia, as shown by our data and previous reports 35, 36 , suggests coordination between epigenetic factors and HIF-mediated post-transcriptional machinery 37 to differentially regulate miR-25/93 levels. These data also reveal the complexity of the role played by Supplementary Table 4 .
5hmC and TET in regulating cellular responses to hypoxia. This is also supported by our observations ( Supplementary Fig. 8c ), as well as recent reports [38] [39] [40] , indicating an uncoupling of expression of the MCM7 gene (host gene for the miR-106b-25 cluster) with the differential expression of members of the miR-106b-25 cluster. Recently, miR-25/93 has emerged as an important onco-miRNA during tumorigenesis 41 , and here we further reveal its function in inducing immunosuppressive phenotypes. To promote immune avoidance, miR-25/93 repressed cGAS by disrupting the epigenetic machinery that maintains basal levels of cGAS (this machinery includes NCOA3). Activation of the cGAS-dependent cytosolic DNA sensing pathway within tumourresident immune cells results in anti-tumour immunity, which contributes to tumour regression 42 . We observed consistent repression of cGAS by hypoxia in different cell types, although miR-25/93 is probably not essential for this effect in every case. Thus, we conclude that the repression of cGAS-IFN signalling in tumour cells is a critical event during cancer progression, indicating a critical role for hypoxia-induced cell-intrinsic immune tolerance in the development of tumours. Interestingly, differences in tumour-infiltrating immune cells (for example, CD4+ T cells and MDSCs) between different experimental settings (for example, Supplementary Figs 1  and 3 ) suggest that hypoxia-responsive molecules regulate a diversity of immunosuppressive pathways. Thus, further analyses are required to understand the interplay between the tumour microenvironment and tumour immune responses. Excessive DAMPs influence immunity and are associated with inflammatory responses, which contribute to many chronic diseases, including cancer 43 . mtDNA represents one type of DAMP. During cancer progression, hypoxia induces the intracellular translocation and release of mtDNA 26 , which may contribute to immunological stress. We observed increased levels of cytoplasmic mtDNA in hypoxic cells, leading to the induction of an immune response. This immune response was inhibited by the hypoxia-TET1-miR-25/93 signalling axis, suggesting a direct link between hypoxia-responsive miRNAs and immune tolerance to DAMP-induced immunological stress. In summary, our results highlight the link between cGAS downregulation and tumour immunosuppression, and implicate miR-25/93 as a central regulator that acts in concert with hypoxia to regulate immune escape from DAMP-induced immunological pressure. These findings have potential implications for anticancer immunotherapies.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3615
M E T H O D S
METHODS Cells, plasmids, stable transfection and oxygen deprivation. The E0771 murine breast cancer cell line (CH3 BioSystems) was maintained in RPMI medium supplemented with 10% FBS and 1% penicillin/streptomycin. MCF7 and MDA-MB-231 cell lines (ATCC) were cultured in DMEM medium supplemented with 10% FBS at 37 • C in the presence of 5% CO 2 . Cells were routinely tested for mycoplasma contamination (once every month). A pcDNA3 mHIF-1α-MYC (P402A/P577A/N813A) (Addgene) plasmid was used for generating HIF-1α overexpression clones in E0771 cells. A pBabe-NCOA3 expression vector was used for NCOA3 re-expression in human breast cancer cells. The plasmids for gene knockdown experiments were generated by inserting an oligonucleotide targeting a specific gene sequence into the pSUPER vector (Oligoengine). These vectors were then used to establish stable transfectants. For miRNA inhibition, MISSION LentimiRNA inhibitors (Sigma) targeting miR-25 and miR-93 were used to generate stable transfectants in MCF7 or MDA-MB-231 cells. For miRNA overexpression, the MDH1-PGK-GFP vector (Addgene) was used to express human or mouse miR-25/93 in human breast cancer cells or murine breast cancer cell, respectively. Oxygen deprivation was conducted in a hypoxic incubator with 1% O 2 , 5% CO 2 and 94% N 2 for 18 or 24 h.
Western blot analysis, RNA extraction and quantitative real-time PCR.
Western blot was performed following standard protocols, as described previously 19 . Briefly, cells were harvested and lysed using RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate, 1% NP-40). Protein extracts were subjected to SDS-PAGE analysis. The membranes were blocked with 5% non-fat milk followed by antibody hybridization and the signals were visualized on X-ray film. For RNA extraction, total RNAs from cultured cells were extracted using the Trizol reagent (Invitrogen Life Technologies), and 1 µg of RNA was used for cDNA synthesis. Quantitative realtime PCR was carried out to quantify gene expression levels by using the CFX384 Touch Real-Time PCR Detection System (BIO-RAD Laboratories). For measuring mtDNA in cytosol, as described previously 44 , the Mitochondria Isolation Kit (Thermo Fisher Scientific) was used to isolate cytosolic, mitochondrial and nuclear fractions from cancer cells. Primers for human cytochrome B, human cytochrome C oxidase subunit III and human NADH dehydrogenase were used in qPCR analysis. Cytoplasmic mtDNA levels were normalized to nuclear DNA encoding 18S ribosomal RNA. The antibodies and primers used in the experiments are listed in Supplementary Table 3 .
Luciferase reporter assays. Cells were seeded onto 6-well plates and transfected with the following: psiCheck2 luciferase reporter plasmid containing wild-type or mutated Ncoa3 3 -UTR and expression vector encoding human miR-25/93. Transfected cells were exposed to 20% or 1% O 2 for 24 h. Luciferase activity in cell lysates was measured using the Dual-Luciferase Reporter Assay System (Promega).
qPCR-ChIP and hMeDIP. qPCR-ChIP assay was performed as described previously 45 . Briefly, crosslinked cell lysate was sonicated and subjected to an immunoprecipitation reaction with specific-antibody-conjugated beads. The immunoprecipitated DNA was purified through a phenol-chloroform DNA extraction protocol and then subjected to qPCR analysis. For the hMeDIP assay, genomic DNA was prepared with the genomic DNA extraction kit (Promega) and sonicated into fragments of ∼500 base pairs. Fragmented DNA was denatured for 10 min at 95 • C and immunoprecipitated overnight at 4 • C with anti-5hmC antibody (Active Motif) in 500 µl IP buffer (10 mM sodium phosphate, 140 mM NaCl, 0.05% Triton X-100). DNA was eluted from the beads followed by purification with the chromatin IP DNA purification kit (Active Motif).
Flow cytometry and cytokines secretion assays.
Cell surface marker staining and flow cytometric analysis for CD3, CD4, CD8, CD45, F4/80 and CD11b (Biolegend) expression was performed as described previously 46 . For MDSC analysis, mouse MDSC flow cocktail kit (Biolegend) was used. For intracellular staining for Foxp3 (Biolegend), True-Nuclear Transcription Factor Buffer Set (Biolegend) was used. To measure T-cell cytokine production for effector CD8 + cytotoxic T cells, TICs were treated with Cell Activation Cocktail (Biolegend) for at least 4 h at 37 • before staining for TNF and IFN-γ (Biolegend).
In vivo models. All animal studies were performed under protocols approved by the Institutional Review Board of the Salk Institute for Biological Studies, La Jolla, USA. This study is compliant with all relevant ethical regulations regarding animal research. Cells were trypsinized and resuspended in PBS/Matrigel (1:1; BD Biosciences). Suspended cells were then subjected to mammary fat pad injection or subcutaneous injection of C57BL/6 mice or IfnαβR −/− mice. Tumour size was measured by calliper. Tumour biospecimens were collected at a similar size for immune cell profiling analysis or gene expression analysis. After six weeks, all of the tumours were collected and the animals were euthanized.
High-throughput whole-transcriptome (mRNA-seq) and small RNA-seq. Total RNA was isolated by the Trizol reagent (Invitrogen Life Technologies) and treated with DNase. Invitrogen Qubit and Agilent Tape Station were used to determine RNA concentration and RNA integrity (RIN) numbers respectively, prior to library preparation. Stranded mRNA-seq libraries were prepared using the Illumina TruSeq Stranded mRNA Library Prep Kit according to the manufacturer's instructions. Briefly, RNA with a poly-A tail was isolated using magnetic beads conjugated to poly-T oligonucleotides. mRNA was then fragmented and reverse-transcribed into cDNA. dUTPs were incorporated, followed by second-strand cDNA synthesis. The dUTP-incorporated second strand was not amplified. cDNA was then end-repaired, index adaptor-ligated and PCR amplified. AMPure XP beads (Beckman Coulter) were used to purify nucleic acid after each step of the library preparation. Small RNA libraries were generated using the NEB Next Multiplex Small RNA Library Prep Set for Illumina according to the vendor's instructions (New England Biolabs). Briefly, 3 SR Adaptor was ligated to short RNAs at 25 • C for 1 h. SR RT Primer was added to hybridize any unligated 3 SR adaptor to prevent adaptor-dimer formation. 5 SR Adaptor was then ligated, followed by reverse transcription and PCR amplification to add indexes to each library. Amplified libraries were TBE-PAGE gel-purified (130-150 bp). All sequencing libraries were then quantified, pooled and sequenced at single-end 50 base-pair (bp) on Illumina HiSeq 2500 at the Salk NGS Core. Raw sequencing data was de-multiplexed and converted into FASTQ files using CASAVA (v1.8.2).
RNA-seq analysis.
Sequenced reads were quality-tested using FASTQC and aligned to the hg19 human genome using the STAR aligner. Mapping was carried out using default parameters (up to ten mismatches per read, and up to nine multi-mapping locations per read). The genome index was constructed using the gene annotation supplied with the hg19 Illumina iGenomes collection and a sjdbOverhang value of 100. FPKM normalized expression was quantified across all gene exons (RNA-seq), using the top-expressed isoform as a proxy for gene expression, and differential genes were defined as having a log 2 -fold change >0.5 after the addition of a pseudocount of 5 to control for low-expressing noisy genes. The normalized expression table for all genes, and lists of differential genes is provided as Supplementary Data.
Clinical sample collection and evaluation of immunohistochemistry. Adequate surgical specimens from 148 breast invasive ductal carcinoma patients with relevant pathological information were collected from 1992 to 2005. This study was approved by The Institutional Review Board, Salk Institute for Biological Studies. The study is compliant with all relevant ethical regulations and informed consent was obtained from all participants. Tissue microarray slides were comprised of 45 grade I cases, 53 grade II cases and 50 grade III cases. The histopathological differentiation of breast invasive ductal carcinoma was determined on the basis of the WHO classification criteria for tumours. The pathological diagnosis for each case was under blind examination by at least two senior pathologists. Immunohistochemistry was performed using an EnVision Dual Link System-HRP (DAB+) kit. To evaluate the immunoreactivity of cGAS, cases were scored from 0 to 3+ (0, negative; 1+, low expression; 2+, intermediate expression; 3+, high expression) on the basis of the intensity of cGAS staining.
Statistics and reproducibility.
For animal experiments, no statistical method was used to predetermine sample size and the experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All data were reported as mean ± s.d. Statistical analysis was performed by using Student's t-test and P < 0.05 was considered significant. The prognostic significance of the clinicopathological parameters related to survival rate was assessed by Kaplan-Meier analysis. All statistical analyses were performed using SPSS version 20 (SPSS, Inc., Chicago, Illinois, USA). The results relative to miRNA expression in human breast cancer are based on data generated by The Cancer Genome Atlas pilot project (TCGA) established by the NCI and NHGRI. Information about TCGA can be found at http://cancergenome.nih.gov. Supplementary Figure 9 . Statistics source data is available in Supplementary Table 4 .
Relative expression
Relative expression
Il-12b Supplementary Figure 9 . Statistics source data is available in Supplementary Table 4 . Supplementary Figure 9 . Statistics source data is available in Supplementary Table 4 . Corresponding author(s): Juan Carlos Izpisua Belmonte
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Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined. For gene expression level analysis by qPCR, combining a technical duplicate/ triplicate (intra-sample variability) with a biological triplicate (inter-experiment variability) was applied to detect a pre-specified effect size whilst working with relatively small sample size. For animal study, at least five mice were used to ensure the enough sample size for statistical analysis.
Data exclusions
Describe any data exclusions. No inclusion/exclusion criteria was applied in this study.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No method of randomization was required.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The present study did not require the use of blinded experiments.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted Describe the software used to analyze the data in this study.
There was no special code used to generate the RNA-seq analysis or any data in this study.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There is no restriction on availability of materials used in this study.
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
The information is available in Supplementary material. c. Report whether the cell lines were tested for mycoplasma contamination.
Cells were routinely tested for mycoplasma contamination (once every month).
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines used in this study.
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide details on animals and/or animal-derived materials used in the study. C57BL/6 mice and IFNalpha/beta receptor -/-mice were used as a host for tumor formation. The tumors derived from these mice were used for gene expression analysis and immune cell profiling. 8 weeks old female mice were used in this study.
Policy information about studies involving human research participants
Description of human research participants
Describe the covariate-relevant population characteristics of the human research participants.
This study is not a clinical trial study and did not involve human research participants.
